Hormone replacement therapy (HRT) is a well-established therapeutic area for Solvay Pharmaceuticals, both for women and men.

For women, Solvay products have reached a prominent position worldwide for the treatment of menopausal symptoms and complaints. Solvay thinking is in line with current views on the appropriate use of HRT which urges for shorter courses (less than five years) at lower doses.
Solvay recommends patients taking its HRT products to continue, as long as the benefit of alleviation of severe symptoms outweighs the risk. HRT remains attractive for many women as it allows them to control menopausal symptoms such as hot flushes, and permits them to carry out normal professional and private activities.

One of the group’s best-selling pharmaceuticals products, ANDROGEL®, is a treatment for insufficiency of testosterone, an important male hormone.